SP-40,40 is a constituent of Alzheimer's amyloid
The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Abstract
Cerebrospinal fluid (CSF), serum and seminal plasma contain a small amount of SP-40,40, a modulatory protein of the human complement system. The SP-40,40 in each body fluid was different in molecular size on SDS-PAGE, and glioblastoma cells, hepatoma cells and testicular tumor cells produced SP-40,40, while neuroblastoma cells did not. Therefore, it was estimated that CSF SP-40,40 originated in glia cells, serum SP-40,40 in liver cells and seminal plasma SP-40,40 in testicular cells. SP-40,40 concentrations in CSF of the patients with Alzheimer's disease and the patients with cerebral tumor were higher than those of normal donors. beta-Amyloid deposits in the brains of the patients with Alzheimer's disease were stained with an anti-SP-40,40 monoclonal antibody (mAb) but not with an anti-S-protein mAb, while cellular processes around beta-amyloid were stained with an anti-S-protein mAb but not with an anti-SP-40,40 mAb. Therefore, beta-amyloid contained SP-40,40 in a form different from that in the soluble membrane attack complex (SMAC, SC5b-9) of the complement, which contains S-protein as well as SP-40,40.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Clusterin, which is secreted by astrocytes, has been found to complex to soluble Aβ [35], is present in plaques [36–38], and directly activates microglia [39].”
From Microglial dysfunction in brain aging and Alzheimer's disease (2014) · cites this paper as [36]
Citations
Cites
Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4
LAEMMLI, U. K. (1970) · Nature · doi:10.1038/227680a0 · Cited by 249,961 · cited 1×
“SDS-PAGE was performed according to Laemmli [ 16 ] using 10 % polyacrylamide gel.”
MethodRaza, H., John, A., & Nemmar, A. (2013) · Cellular Physiology and Biochemistry · doi:10.1159/000350087 · Cited by 47,221
[1] Preparation of monoclonal antibodies: Strategies and procedures
Galfrè, G., & Milstein, C. (1981) · Methods in Enzymology · doi:10.1016/0076-6879(81)73054-4 · Cited by 1,771
Abraham, C. R., Selkoe, D. J., & Potter, H. (1988) · Cell · doi:10.1016/0092-8674(88)90462-x · Cited by 900 · cited 1×
“A remarkable feature of SP-40,40 was its specific accumulation in ~-amyloid deposits in the brains of the patients with AD. Several proteins such as amyloid P component [6], complement proteins (Clq, C3 fragments and C4) [8] and cq-antichymotrypsin [ 1 ] are also accumulated in ~-amyloid of AD. At present no functiona…”
BackgroundImmunoglobulins and complement factors in senile plaques: An immunoperoxidase study
Eikelenboom, P., & Stam, F. C. (1982) · Acta Neuropathologica · doi:10.1007/bf00685397 · Cited by 454
Jenne, D. E., & Tschopp, J. (1989) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.86.18.7123 · Cited by 414
Biosynthesis and molecular cloning of sulfated glycoprotein 2 secreted by rat Sertoli cells
Collard, M. W., & Griswold, M. D. (1987) · Biochemistry · doi:10.1021/bi00386a008 · Cited by 330 · cited 1×
“SGP-2 appears to participate in the spermatogenesis [ 5 ].”
BackgroundMurphy, B. F., Kirszbaum, L., Walker, I. D., & d'Apice, A. J. (1988) · Journal of Clinical Investigation · doi:10.1172/jci113531 · Cited by 313 · cited 1×
“SP-40,40 was discovered as a component in the soluble membrane attack complex (SMAC, SC5b-9) of human complement [2, 18 ].”
BackgroundMassive somatodendritic sprouting of cortical neurons in Alzheimer's disease
Ihara, Y. (1988) · Brain Research · doi:10.1016/0006-8993(88)90293-4 · Cited by 304 · cited 1×
“Staining of sections of formalin-fixed brain was performed according to Ihara [ 12 ].”
MethodSelf-citationChanges in brain gene expression shared by scrapie and Alzheimer disease.
Duguid, J. R., Bohmont, C. W., Liu, N. G., & Tourtellotte, W. W. (1989) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.86.18.7260 · Cited by 251 · cited 3×
“Although Duguid [ 7 ] reported that SP-40,40-1ike mRNA markedly increased in hippocampus from the patients with AD, the concentration of SP-40,40 in CSF from the patients with AD was not as high as expected.”
BackgroundInfluential
Cited by
Items 101–168 of 168
Morales-Corraliza, J., Schmidt, S. D., Mazzella, M. J., Berger, J. D., Wilson, D. A., Wesson, D. W., Jucker, M., Levy, E., Nixon, R. A., & Mathews, P. M. (2013) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2012.04.007 · Cited by 34
Lidström, A.-M., Hesse, C., Rosengren, L., Fredman, P., Davidsson, P., & Blennow, K. (2001) · Journal of Alzheimer’s Disease · doi:10.3233/jad-2001-3501 · Cited by 32
Nishida, K., Quantock, A. J., Dota, A., Choi-Miura, N.-H., & Kinoshita, S. (1999) · British Journal of Ophthalmology · doi:10.1136/bjo.83.10.1178 · Cited by 33
Self-citationExpression of Apolipoprotein J in the Uterus is Associated with Tissue Remodeling1
Brown, T. L., Moulton, B. C., Baker, V. V., Mira, J. L., & Harmony, J. A. K. (1995) · Biology of Reproduction · doi:10.1095/biolreprod52.5.1038 · Cited by 33
Aizawa, Y., Fukatsu, R., Takamaru, Y., Tsuzuki, K., Chiba, H., Kobayashi, K., Fujii, N., & Takahata, N. (1997) · Brain Research · doi:10.1016/s0006-8993(97)00640-9 · Cited by 31
Ogawa, S., Ishibashi, Y., Sakamoto, Y., Kitamura, K., Masanori, K. U. B. O., Sakai, T., & Inoue, K. (1997) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1997.6704 · Cited by 31
Cardoso, I., Brito, M. A., & Saraiva, M. J. (2008) · Disease Markers · doi:10.1155/2008/549872 · Cited by 31
“: +351 22 6074900; Fax: +351 22 6099157; E-mail: mjsaraiv@ibmc.up.pt.”
Post-Translational Modifications in Alzheimer's Disease and the Potential for New Biomarkers
Russell, C. L., Končarević, S., & Ward, M. A. (2014) · Journal of Alzheimer s Disease · doi:10.3233/jad-132312 · Cited by 27
“Furthermore, clusterin is found to be associated with A deposits and dystrophic neurites in senile plaques in the frontal cortex and hippocampus of AD brains, shown by immunoreactivity experiments [114, 115].”
Serra, J. A., Famulari, A. L., Kohan, S., Marschoff, E. R., Domínguez, R. O., & de Lustig, E. S. (1994) · Journal of the Neurological Sciences · doi:10.1016/0022-510x(94)90297-6 · Cited by 27
Increase in clusterin-containing follicles in the adenohypophysis of drug abusers
Ishikawa, T., Zhu, B.-L., Miyaishi, S., Ishizu, H., & Maeda, H. (2006) · International Journal of Legal Medicine · doi:10.1007/s00414-006-0138-2 · Cited by 25
“Clusterin was recently found in senile plaques in the brains of patients with Alzheimer’s disease [14], and it was further shown that clusterin binds abnormal proteins [15, 16], prion disease [17], and ischemia [18].”
BackgroundStudies on the first described Alzheimer's disease amyloid β mutant, the Dutch variant
Levy, E., Prelli, F., & Frangione, B. (2006) · Journal of Alzheimer's Disease · doi:10.3233/jad-2006-9s337 · Cited by 24
“…the major constituent of the amyloid deposits in AD, there are minor components such as P-component [26], apolipoprotein E [88], apolipoprotein J [20,78], proteoglycans [108], lysosomal proteinases [4,5,18,87,92] and the proteinases inhibitors, α 1 -antichymotrypsin, α 1-antitrypsin [1,44], α 2…”
Clusterin Binding Modulates the Aggregation and Neurotoxicity of Amyloid-β(1–42)
Kim, Y., Park, S., Choi, S. Y., Oh, S. B., Jung, M., Pack, C., Hwang, J. J., Tak, E., & Lee, J. (2022) · Molecular Neurobiology · doi:10.1007/s12035-022-02973-6 · Cited by 23
Kloučková, J., Lacinová, Z., Kaválková, P., Trachta, P., Kasalicky, M., Haluzíková, D., Mráz, M., & Haluzík, M. (2016) · Physiological Research · doi:10.33549/physiolres.933121 · Cited by 21
Yu, V., Bhattacharya, D., Webster, A., Bauskar, A., Flowers, C. W., Heur, M., Chintala, S. K., Itakura, T., Wilson, M. R., Barr, J. T., et al. (2018) · The Ocular Surface · doi:10.1016/j.jtos.2018.08.001 · Cited by 21
Age-dependent increase of clusterin in the human pituitary gland
Ishikawa, T., Zhu, B.-L., Li, D., Zhao, D. H., Michiue, T., & Maeda, H. (2005) · Legal Medicine · doi:10.1016/j.legalmed.2005.08.009 · Cited by 21
“[28,29], and it was shown that clusterin was a major binding protein of b-amyloid [30].”
BackgroundSulfated Glycoprotein‐2: An Emerging Molecular Marker for Neurodegeneration
May, P. C. (1993) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1993.tb18303.x · Cited by 21
Strategies for Inhibition of Complement Activation in the Treatment of Neurodegenerative Diseases
Spiegel, K., Emmerling, M. R., & Barnum, S. R. (1998) · Humana Press eBooks · doi:10.1007/978-1-59259-473-3_5 · Cited by 22
Quantification of clusterin in paired cerebrospinal fluid and plasma samples
Jongbloed, W., Herrebout, M. A. C., Blankenstein, M. A., & Veerhuis, R. (2013) · Annals of Clinical Biochemistry International Journal of Laboratory Medicine · doi:10.1177/0004563213503456 · Cited by 20
“Clusterin and ApoE are associated with different types of amyloid plaques, including diffuse type plaques, suggesting a role of these transporter proteins in the earliest stages of amyloid deposition.(9,12,13,16) Interestingly in CSF, clusterin was found to be present as a complex with A .”
BackgroundInflammatory Mediators in Alzheimer’s Disease
Rogers, J., & O’Barr, S. A. (1997) · Humana Press eBooks · doi:10.1007/978-1-59259-471-9_11 · Cited by 19
Clusterin in Human Corneal Endothelium and Aqueous Humor
Dota, A., Nishida, K., Quantock, A. J., & Kinoshita, S. (1999) · Experimental Eye Research · doi:10.1006/exer.1999.0757 · Cited by 18
Apolipoprotein E and Amyloidogenesis
Frangione, B., Castaño, E. M., Wısnıewskı, T., Ghiso, J. A., Prelli, F., & Vidal, R. (2007) · Novartis Foundation symposium · doi:10.1002/9780470514924.ch9 · Cited by 18
Extracellular chaperone networks and the export of J-domain proteins
Braun, J. E. A. (2022) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2022.102840 · Cited by 17
Montoliu‐Gaya, L., Mulder, S. D., Veerhuis, R., & Villegas, S. (2017) · PLoS ONE · doi:10.1371/journal.pone.0188191 · Cited by 18
Choi-Miura, N.-H., Sakamoto, T., Ohtaki, S., Nakamura, H., Ishizawa, S., Takagi, Y., GOMI, K., & Tomita, M. (1993) · Clinical & Experimental Immunology · doi:10.1111/j.1365-2249.1993.tb07973.x · Cited by 17
Self-citationProtein Misfolding Disorders and Rational Design of Antimisfolding Agents
Estrada, L. D., Yowtak, J., & Soto, C. A. (2006) · Humana Press eBooks · doi:10.1385/1-59745-116-9:277 · Cited by 16
Immunohistochemical Presence of Apolipoprotein D in Senile Plaques
Navarro, A., Astudillo, A., del Valle, E., del Rey, C. G., & Tolivia, J. (2001) · Journal of Histotechnology · doi:10.1179/014788801794812732 · Cited by 16
Tsuzuki, K., Fukatsu, R., Takamaru, Y., Yoshida, T., Hayashi, Y., Yamaguchi, H., Fujii, N., & Takahata, N. (1995) · Neuroscience Letters · doi:10.1016/0304-3940(95)12205-2 · Cited by 16
Martá-Ariza, M., Leitner, D. F., Kanshin, E., Suazo, J., Giusti Pedrosa, A., Thierry, M., Lee, E. B., Devinsky, O., Drummond, E., Fortea, J., et al. (2025) · Acta Neuropathologica · doi:10.1007/s00401-025-02844-z · Cited by 15
Do Amyloid β-associated Factors Co-deposit with Aβ in Mouse Models for Alzheimer's Disease?
Timmer, N., Kuiperij, H. B., de Waal, R. M. W., & Verbeek, M. M. (2010) · Journal of Alzheimer s Disease · doi:10.3233/jad-2010-100711 · Cited by 15
“Indeed, this apolipoprotein, but also ApoD, is known to co-deposit with Aβ [60,73] and furthermore ApoJ could decrease Aβ aggregationin vitro [74] and in vivo [75].”
Rajput, P. S., Billová, S., Patel, S. C., Kharmate, G., Somvanshi, R. K., & Kumar, U. (2009) · Journal of Chemical Neuroanatomy · doi:10.1016/j.jchemneu.2009.05.004 · Cited by 15
“Besides ApoE, Apolipoprotein J (ApoJ) and Apolipoprotein D (ApoD) have also shown to play a crucial role in the AD as well as in several other neurological disorders (Choi-Miura et al., 1992; Terrisse et al., 1998, 1999; Calero et al., 2000; Kalman et al., 2000; Belloir et al., 2001; Thomas et al., 2001; DeMattos et a…”
BackgroundTsuzuki, K., Fukatsu, R., Takamaru, Y., Yoshida, T., Mafune, N., Kobayashi, K., Fujii, N., & Takahata, N. (1995) · Brain Research · doi:10.1016/0006-8993(95)00917-f · Cited by 15
Berdowska, I., Matusiewicz, M., & Krzystek‐Korpacka, M. (2022) · Antioxidants · doi:10.3390/antiox11030524 · Cited by 14
“The CSF clusterin is suggested to originate from the brain and not the blood [168].”
BackgroundInflammatory Mechanisms of Alzheimer’s Disease
Rogers, J., & Griffin, W. S. T. (1998) · Humana Press eBooks · doi:10.1007/978-1-59259-473-3_6 · Cited by 14
Peripheral Markers and Diagnostic Criteria in Alzheimer's Disease: Critical Evaluations
de Lustig, E. S., Kohan, S., Famulari, A. L., Domínguez, R. O., & Serra, J. A. (1994) · Reviews in the Neurosciences · doi:10.1515/revneuro.1994.5.3.213 · Cited by 14
Extracellular Chaperones and Amyloids
Wilson, M. R., Yerbury, J. J., & Poon, S. (2008) · Springer eBooks · doi:10.1007/978-1-4020-8231-3_15 · Cited by 12
“Clusterin is a protein secreted from many different cell types that is found in human plasma, CSF and seminal fluid at concentrations of approximately 100, 2, and 1000 µg/ml (Fritz et al., 1983; Murphy et al., 1988; Choi-Miura et al., 1992), respectively.”
Upregulation of clusterin/apolipoprotein J in lactacystin‐treated SH‐SY5Y cells
Carreras, I., Garrett-Young, R., Ullman, M. D., Eisenhauer, P. B., Fine, R. E., Wells, J. M., & Conn, K. J. (2005) · Journal of Neuroscience Research · doi:10.1002/jnr.20374 · Cited by 11
“, 1997) and is induced after tissue injury and in many disease states such as glomerulonephritis, polycystic kidney disease, renal tubular injury, atherosclerosis, myocardial infarction, and neurodegenerative conditions including Alzheimer’s disease (AD) where it associated with amyloid plaques (Choi-Miura et al., 199…”
BackgroundJanciauskiene, S. M., Sun, Y., & Wright, H. T. (2002) · Neurobiology of Disease · doi:10.1006/nbdi.2002.0519 · Cited by 7
“, 1996), is a component of amyloid plaques (Namba et al., 1991; Choi-Miura et al., 1992; Wisniewski & Frangione, 1992; Charge et al., 1996), and is known to interact with A in vivo (Wisniewski et al.”
BackgroundMolecular Pathobiology of Alzheimer’s Disease
Harrington, C. R., & Wischik, C. M. (1994) · Springer eBooks · doi:10.1007/978-1-4615-6805-6_13 · Cited by 5
Larson, D., Kennedy, M. A., Bowen, R. F., Verchere, C. B., & Deeg, M. (2004) · The Journal of Pathology · doi:10.1002/path.1600 · Cited by 4
Choi-Miura, N.-H. (2001) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.24.39 · Cited by 4
Self-citationApolipoproteins in Different Amyloidoses
Sadowski, M., & Wısnıewskı, T. (2007) · Springer eBooks · doi:10.1007/0-387-25919-8_6 · Cited by 3
Rother, K. O., Till, G. O., & Hänsch, G. M. (1998) · Springer eBooks · doi:10.1007/978-3-642-58753-5_1 · Cited by 3
Cellular and molecular mechanisms of Alzheimer’s disease inflammation
Peery, H. E., Strohmeyer, R., & Rogers, J. (2001) · Birkhäuser Basel eBooks · doi:10.1007/978-3-0348-8350-4_1 · Cited by 2
Vascular Transport of Alzheimer’s Amyloid β Peptides and Apolipoproteins
Zloković, B. V., Ghiso, J. A., & Frangione, B. (2000) · Springer eBooks · doi:10.1007/978-94-017-1007-7_20 · Cited by 2
Exploring Amyloidogenicity of Clusterin: A Structural and Bioinformatics Analysis
Tsiolaki, P. L., Nastou, K. C., Louros, N. N., Hamodrakas, S. J., & Iconomidou, V. A. (2017) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-57348-9_8 · Cited by 1
Apolipoprotein E: Structural and Functional Interactions with Amyloid β
Stine, W. B., & LaDu, M. J. (2005) · Wiley eBooks · doi:10.1002/9783527619344.ch10 · Cited by 1
The functional studies of amyloid fibrils and their toxicity
Elias, A. K. (2016) · Adelaide Research & Scholarship (AR&S) (University of Adelaide) · doi:10.4225/55/5837c388b5509 · Cited by 1
Detailed analysis of modulating effects of Clusterin in insulin and IGF-1 signal transduction
Renner, B. (2017) · Gutenberg Open Science · doi:10.25358/openscience-1381 · Cited by 1
Baiersdörfer, M. (2006) · Gutenberg Open Science · doi:10.25358/openscience-891 · Cited by 1
Müller, T. (. (2005) · URN:NBN Resolver for Germany & Switzerland (German National Library) · Cited by 1
Rôle des ADAM dans le processus physiopathologique de la maladie d'Alzheimer
Laumet, G. O. (2010) · theses.fr (ABES) · doi:10.70675/94126786zf990z488ezb471z5f1d5686766c · Cited by 1
Neuroprotective Ganglioside Derivatives
Conn, K. J., DOHERTY, S., Eisenhauer, P. B., Fine, R. E., WELLS, J., & Ullman, M. D. (2003) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2003.tb07498.x
Aufnahme, Abbau und Bindung von ApoE(3/3)- versus ApoE(4/4)-Liposomen in hippokampalen Zellen
Medizin, E., & Beisiegel†, U. (2004)
Familial amyloidotic polyneuropathy : Study of structural determinants in amyloidogenesis
Redondo, A. C. C. (2002) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT) · doi:10.34626/fnp9-d232
Identification and Role of Non-Beta Components of Senile Plaque Amyloid in Alzheimer’s Disease
Takamaru, Y., Fukatsu, R., Tsuzuki, K., Chiba, H., Kobayashi, K., Nagasawa, S., Aizawa, Y., Fujii, N., Takahata, N., & Ueno, T. (1995) · Advances in behavioral biology · doi:10.1007/978-1-4757-9145-7_23
男性不妊症におけるClusterin (SP-40, 40) に関する研究
金, 正., 劉, 滬., 小橋川, 啓., 坂本, 英., 渡辺, 政., 吉田, 英., 三浦, 南., 戸部, 敞., & 富田, 基. (1996) · 昭和医学会雑誌 · doi:10.14930/jsma1939.56.133
Pathological Changes in the Elderly Human Brain
Mann, D. M. A. (1997) · Springer eBooks · doi:10.1007/978-1-4615-6001-2_2
Lange, K. (2017) · OPen Access Repositorium der Universität Ulm (OPARU) (Ulm University) · doi:10.18725/oparu-11761
Charakterisierung und funktionelle Analyse verschiedener Isoformen von Clusterin (Apolipoprotein J)
Prochnow, H.-P. (2014) · Gutenberg Open Science · doi:10.25358/openscience-5195
Apolipoprotein E in Alzheimer's disease
Beffert, U. (1999) · eScholarship@McGill (McGill) · doi:10.82308/24738
Wener, K. M. (1995) · eScholarship@McGill (McGill) · doi:10.82308/3855
Studies on amyloid formation in familial amyloidotic polyneuropathy
Bonifácio, M. J. M. D. S. (1996) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT) · doi:10.34626/207f-1193
The Use of Localized Proteomics to Understand the Pathogenesis of Alzheimer's Disease
Pires, G. (2021) · theses.fr (ABES) · doi:10.70675/45826fd6zd2c8z4b3dz91e0za5080544cb17
Rawal, P., Moon, H.-J., Nguyen, V., Khatri, S., Larson, M. A., Vivian, J. C., Saido, T. C., & Zhao, L. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.07.30.741791
Byrne, R. A. J., Veteleanu, A., Cramp, H. L., Bacon, O. G., Baillie, K. L., Bright, M., Cooke, R. S., Fenn, G. D., Castelán, M. F., Lee, K. Y., et al. (2026) · Alzheimer s & Dementia · doi:10.1002/alz.71885
“Co-localization of clusterin with A β plaques in AD brain was described over thirty years ago, 16,56–58 but glial staining was not reported, suggesting that the reagents used in these studies detected Bassoon and Homer1) positive for clusterin (mAb 4C7) showed no significant difference between Ctrl…”
Khan (2000) · doi:10.1002/1531-8249(200008)48:2
Metadata
- Authors
- Choi-Miura, N. H., Ihara, Y., Fukuchi, K., Takeda, M., Nakano, Y., Tobe, T., & Tomita, M.
- Affiliations
- SHOWA Medical University (JP)
- Tokyo Metropolitan Institute of Gerontology (JP)
- Venue
- Acta Neuropathologica
- Published
- 1992-02
- Volume
- 83
- Issue
- 3
- Pages
- 260-264
- ISSN
- 0001-6322 (ISSN-L)
- 1432-0533
- OpenAlex
- W2089421296
- Cited by
- 158
- References
- 21
- Citations by year
- 2026: 2 · 2025: 1 · 2022: 6 · 2021: 3 · 2018: 2 · 2017: 2 · 2016: 3 · 2014: 2 · 2013: 1 · 2012: 6
- FWCI
- 7.36
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Acta Neuropathologica (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Immunology and Microbiology › Immunology › Complement system in diseases
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- Alzheimer's disease, amyloid-beta, complement system, S protein, cerebrospinal fluid, seminal plasma, serum, glioblastoma, membrane attack complex, sC5b-9, amyloid deposits, monoclonal antibodies
- MeSH terms
- Alzheimer Disease, Amyloid, Antibodies, Blood Proteins, Enzyme-Linked Immunosorbent Assay, Glycoproteins, Humans, Staining and Labeling, Sulfates, Tumor Cells, Cultured, Molecular Chaperones, Clusterin
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.